Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis
top of page
News
Search
Elevated QOL in NCFBE patients with ARINA-1 treatment. Robust data show significant symptom improvement surpassing clinical thresholds.
Renovion
Jan 112 min
Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis
Renovion Inc., a company focused on restoring lung health in patients with bronchiectasis, announces patient enrollment for Phase 2 trial.
Renovion
Oct 10, 20231 min
Interview with the Lung Transplant Foundation: Participating in a Lung Transplant Clinical Trial
Carolyn Durham, CSO at Renovion and Amy S., ED at the LTx Foundation discuss real-world experience of being in a clinical trial in LTx.
Renovion
Apr 18, 20232 min
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Source | Business Wire April 18, 2023 08:52 AM Eastern Daylight Time CHAPEL HILL, N.C - Renovion, Inc. today announced that the first...
Renovion
Apr 3, 20231 min
Double breath of fresh air for Triangle startup: $15M in new cash, fast track status for treatment
Startup Renovion, its marketing slogan “Restoring Lung Health One Breath at a Time,” has gotten two doses of fresh air for its treatment eff
Renovion
Mar 30, 20232 min
Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in LT
The Fast Track designation accelerates the FDA regulatory path for ARINA-1 for the prevention of bronchiolitis obliterans syndrome (BOS)...
Renovion
Nov 2, 20223 min
First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE
Renovion and COPD Foundation Joint Release – Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical...
Renovion
Aug 2, 20222 min
Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program
Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for serious chronic inflammatory lung diseases...
Renovion
Apr 12, 20223 min
Marty Zamora, MD, joins Renovion, Inc. as Chief Medical Officer
Renovion today announced that Dr. Martin “Marty” Zamora, MD, has joined Renovion as Chief Medical Officer. Dr. Zamora will lead the Phase...
bottom of page